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Objectives: To assess the temporal relationship between initiating biologic therapy and 
magnetic resonance imaging (MRI) scores of inflammation and structural damage in young 
patients with spondyloarthritis. 
Methods: A local adolescent rheumatology database was searched for patients aged 12 – 24 
years with sacroiliitis on MRI and a clinical diagnosis of enthesitis-related arthritis (ERA) or 
non-radiographic axial spondyloarthritis. Patients treated with tumour necrosis factor 
inhibitor (TNFi) therapy with a minimum of one scan before and two after starting TNFi 
therapy (over  2 years) were included. Images of the sacroiliac joints were scored for 
inflammation and structural abnormalities (including erosions, fat metaplasia and fusion). 
The effects of TNFi therapy and of time since initiation of TNFi therapy on inflammation and 
structural abnormalities were assessed using a mixed-effects regression analysis.   
Results: Twenty-nine patients aged 12-23 years undergoing TNFi therapy were included. 
Inflammation scores were significantly lower in patients on treatment (P=0.013), but there 
was no significant effect of time from TNFi initiation on inflammation (P=0.125).  Conversely, 
there was no significant effect of treatment itself on fusion scores (P=0.285), but fusion 
scores significantly increased with time from TNFi initiation (P=0.000). A similar pattern was 
observed for fat metaplasia. Fusion scores did not change in the first year after starting TNFi 
therapy (P=0.108), but were significantly increased at all subsequent time points (P=0.000 to 
0.001). 
Conclusions: TNFi therapy failed to prevent the eventual development of joint ankylosis in 
this cohort, despite a substantial reduction in inflammation with TNFi therapy.  
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INTRODUCTION 
The spondyloarthritides are a group of immune-mediated inflammatory disorders 
characterised by inflammation of the spine, entheses and peripheral joints. Ankylosing 
spondylitis (AS) is the ‘prototypic’ spondyloarthritis and causes ankylosis (fusion) of the axial 
skeleton with subsequent disability, morbidity and impaired quality of life (1). However, 
ankylosis may be less severe or absent in other spondyloarthritis subgroups, suggesting that 
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with non-radiographic axial spondyloarthritis have little or no structural damage, whilst 
paediatric patients with spondyloarthritis – who are typically diagnosed with  enthesitis-
related arthritis (ERA) - may have a similar phenotype (2,3). However, it remains unclear 
whether these patients represent an early form of AS (who simply present before structural 
features develop) or whether they represent a fundamentally different spondyloarthritis 
subtype. Furthermore, it is not known whether treating these patients early in their disease 
might prevent ankylosis. Evidence from the preclinical literature suggests that new bone 
formation may be initiated by an initial inflammatory ‘trigger’ (4,5), whilst data from adult 
spondyloarthritis cohorts suggest that structural damage is often preceded by inflammation 
(6,7). These findings suggest that early, aggressive treatment of spondyloarthritis might 
reduce the stimulus for subsequent ankylosis (8). However, animal models of 
spondyloarthritides unravelled alternative pathways, suggesting an uncoupling of 
inflammation and bone formation, involving different molecular mechanisms, with bone 
morphogenetic protein and Wnt signalling involved in the bone formation pathway (9). In 
adults with established AS, clinical trials of tumour necrosis factor inhibitor (TNFi) therapy 
have produced mixed results but have not shown a clear reduction in spinal radiographic 
progression when compared to historical cohorts never treated with TNFi (10,11).  
Despite their well-recognised efficacy in controlling inflammation, the debate about the role 
of TNFi as disease modifiers in spondyloarthritis continues. In this study, we assessed serial 
magnetic resonance imaging (MRI) scans in young axial spondyloarthritis patients 
undergoing biologic therapy, in order to describe the changes in inflammation and structural 
damage occurring over time. 
 
MATERIALS AND METHODS 
This retrospective study was covered by Institutional Review Board approval from the 
National Research Ethics Service Committee London, Bentham, UK (REC ref: 11/LO/0330). 
Informed consent was waived because of the retrospective nature of the study.  
A local clinical adolescent and young adult rheumatology database was used to identify 
patients aged between 12 and 24 years who had evidence of sacroiliitis on MRI, and had a 
clinical diagnosis of ERA with axial involvement or non-radiographic axial spondyloarthritis 
(2,3). A subsequent search of the picture archiving and communication system was used to 
identify all those who had undergone at least three MRI scans of the sacroiliac joints (SIJs) 
over at least a two-year period, with at least one scan before or at the time of starting 
tumour necrosis factor inhibitor (TNFi) therapy (adalimumab, etanercept or infliximab), and 
at least two scans after starting TNFi therapy. Post-treatment scans were performed either 
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MRI scans were acquired on a 1.5 Tesla MRI system with integrated posterior and anterior 
surface coils, using a specified protocol which included short tau inversion recovery (STIR), 
T1-weighted turbo spin echo and post-gadolinium fat-saturated images of the SIJs and 
thoracolumbar spine. Sequence parameters included: STIR, TR/TE/TI = 4340-
6070/83/150ms, T1W TSE, TR/TE = 475-610/11ms, T1W TSE with fat saturation, TR/TE = 
619-715/11ms. Sacroiliac joint images were acquired in both para-coronal (angled parallel 
to the sacrum) and para-axial (angled perpendicular to the sacrum) planes, and 
thoracolumbar spine images were acquired in the sagittal plane with extended lateral 
coverage. Only the SIJ images were used for the analysis included here.  
MR images of the sacroiliac joints were scored independently by two readers (MHC and 
TJPB) with specific expertise in musculoskeletal imaging and in the assessment of 
spondyloarthritis. The extent of inflammation was assessed on STIR images using the 
Spondyloarthritis Research Consortium of Canada scoring system (13), taking care to 
differentiate between areas of high signal due to skeletal immaturity and bone marrow 
oedema.  Chronic inflammatory (structural) abnormalities were assessed on T1-weighted 
images using a recently proposed structural score, which measures the extent of erosions, 
fat metaplasia and joint fusion (14). For each subject, the images were scored in temporal 
order to enable comparison with previous scans. Readers were blinded to the biologic start 
dates and to the clinical status at the time of each scan.  
The statistical analysis plan was designed to evaluate the effect of treatment and of the time 
from biologic initiation on four outcomes, which were measured using MRI scores: 
inflammation, fat metaplasia, erosions and fusion. For each outcome, we took the mean of 
the two observers’ measurements for the statistical analysis. A mixed-effects model was 
used for each outcome and included, as explanatory variables, treatment (on or off biologic 
therapy) and time from biologic start, and accounted for patient repeated measurement 
dependency. The linear model was compared to more complex models assuming a 
quadratic, cubic and categorical relationship between time and the outcome measures using 
likelihood ratio testing. If this analysis did not reveal a significant improvement for any of 
the more complex models over the linear model at a 5% significance level, then the 
reference results were derived from the linear model. For completeness, the fluctuations 
over time in each of the MRI scores were summarised from the results derived from the 
saturated model, where time was included as a categorical variable. 
We also tested for relationships between inflammation and fusion, between fat metaplasia 
and fusion, between erosions and fusion, and between inflammation and fat metaplasia 
using random intercept and slope models for each of the relationships in question. For 
example, in order to assess whether, adjusting for time, inflammation scores have an effect 
on fusion, a random intercept and slope model was implemented which included fusion as 
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RESULTS 
Twenty-nine patients were included (mean age at biologic start 17y2m, range 12y3m to 
22y10m), including 23 male and six female patients. Twenty-three patients were HLA-B27 
positive, two were negative and four had not been tested. The mean symptom duration at 
the time of starting biologic therapy was 5y3m (range 4m to 11y). 18 patients were treated 
with etanercept, eight with adalimumab and three with infliximab. Five patients switched 
biologics during the follow up period of the study (due to side effects in three cases and due 
to inefficacy in two cases). The mean number of scans performed per patient was 4.5 (range 
3-7), and the mean interval between the first and last scans was 5y2m (range 1y9m to 
9y11m).  
This analysis did not reveal a significant improvement for any of the more complex models 
over the linear model, which was therefore selected for the main analysis.  
Estimates of inflammation, erosions, fat metaplasia and fusion over time derived from the 
linear model are shown in Figure 1. Inflammation scores were significantly lower in patients 
on treatment than not on treatment [regression coefficient (95% CI) = -6.94 (-12.4 to -1.44); 
P=0.013], but there was no significant effect of time since biologic initiation on inflammation 
scores [-0.90 (-2.04 to 0.35); P=0.125]. Conversely, there was no significant effect of 
treatment itself on fusion scores [-0.74 (-2.17 to 0.69; P=0.308] but there was a significant 
positive relationship between time since biologic start and fusion [1.55 (1.02 to 2.09); 
P<0.001]. Similarly, there was no significant effect of treatment per se on fat metaplasia 
scores [1.66 (-1.38 to 4.70); P=0.285], but time since biologic start was significantly 
associated with fat metaplasia [1.53 (0.57 to 2.50); P=0.002]. There was no significant effect 
of either treatment [0.12 (-3.83 to 4.06); P=0.954] or time since biologic initiation [-0.82 (-
1.91 to 0.27); P=0.139] on erosion scores. 
When the effects of time and treatment were accounted for, there was a significant 
negative relationship between inflammation and fat metaplasia [-0.25 (-0.34 to -0.17; 
P<0.001], but no significant relationship between inflammation and fusion [-0.02 (-0.06 to 
0.03); P=0.443], fat metaplasia and fusion [0.04 (-0.04 to 0.12); P=0.305], or erosions and 
fusion [-0.05 (-0.11 to 0.01; P=0.104].  
DISCUSSION 
The spondyloarthritides encompass a wide range of disease phenotypes, which vary in 
terms of disease severity, the presence of structural damage and age at presentation. 
Spondyloarthritis patients who present early might offer a unique opportunity to study the 
disease course, and to characterise the evolution of inflammatory and structural damage 
over time. Additionally, it has been suggested that early intervention might help to avoid 
structural complications and thereby improve long term outcomes (8). However, we 
observed that TNFi therapy did not prevent the eventual fusion of the SIJs in ERA patients, 
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and that inflammation was substantially reduced by TNFi treatment. Although SIJ ankylosis 
in itself may have a relatively small effect on disability, it is possible that the effect of 
treatment on inflammation and structural damage would be similar in the remainder of the 
spine. 
The results of our study do not enable us to comment on the specific cause of fusion in 
these patients; we do not know whether fusion is a consequence of inflammation itself, or 
whether it is related to the TNFi therapy. Although the levels of inflammation were 
substantially reduced after treatment, it is possible that low levels of inflammation persist 
and drive joint ankylosis. Alternatively, joint fusion may be ‘triggered’ by the initial 
inflammatory insult and then proceed independently, as other authors have suggested (4,5). 
Either way, these results suggest that more research is needed into strategies for preventing 
structural damage, either through a reduction in inflammation or the inhibition of bone-
forming pathways.  
Some limitations have arisen due to the retrospective nature of the study. As scan number 
was an inclusion criterion, it is likely that our cohort includes patients with more severe 
disease. However, the severity of this cohort of patients with ‘definite’ spondyloarthritis 
probably also increased the size of the effects in question, which may have actually 
strengthened the analysis we performed.  
An additional issue is that scans were acquired at irregular intervals (as determined by 
clinical need), meaning that the data were not evenly distributed in the post-treatment 
period. Nonetheless, our regression model accounted for the clustered nature of the data, 
reducing any potential effect on the final analysis. It should be emphasised that 
spondyloarthritis in young people is comparatively rare, and it would have been very 
difficult to acquire data over such a long time-period in a prospective fashion.  
The development of imaging methods which could identify new bone formation before the 
development of overt ankylosis might reduce the follow up period needed to assess the 
effect of novel therapies on new bone formation. Several groups have begun to explore MRI 
methods which can derive signal directly from mineralised bone or quantify bone mineral 
density indirectly (15), and it is likely that these techniques will become more widely 
applicable in the years to come.  
In conclusion, we found that TNFi therapy in young patients with spondyloarthritis failed to 
prevent the eventual development of joint ankylosis in a young spondyloarthritis cohort, 
despite a substantial reduction in inflammation with TNFi therapy.  
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Figure 1 – Images from a single patient showing the progression of ankylosis over a five 
year period. Before TNFi therapy (a,b,c) there is bilateral bone marrow oedema shown on 
STIR (a) and T1-weighted (b,c) images. After TNFi therapy (d-g), the joint erosions 
gradually become less distinct, and the joints ultimately fuse in similar anatomical 
locations to the initial oedema.  
 
Figure 2 – Scores for inflammation, erosions, fat metaplasia and fusion over time. 
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